LIFERIVER(SH:688317) 智通财经网·2026-01-22 07:43Core Viewpoint - Zhijiang Biotech (688317.SH) forecasts a net profit attributable to shareholders of the parent company for 2025 to be between -32 million to -47 million yuan, indicating a significant loss compared to the previous year [1] Financial Performance - The expected net profit loss represents an increase in loss of 80.4621 million to 95.4621 million yuan year-on-year, reflecting a reduction in loss margin of 63.13% to 74.89% [1] Reasons for Performance Decline - The primary reasons for the company's performance decline include a decrease in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate for self-produced reagent products to 13%, resulting in decreased revenue [1] - Additional factors contributing to the loss include a decline in financial income and reduced foreign exchange gains [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1]